<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03519308</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 22217</org_study_id>
    <nct_id>NCT03519308</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Micoenvironment in Resectable Pancreatic Cancer</brief_title>
  <official_title>A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Micoenvironment in Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to look at the potential effects of paricalcitol (a drug&#xD;
      similar to vitamin D) and nivolumab on pancreatic tumors in patients who are treated with&#xD;
      gemcitabine and abraxane. The study will also look at the safety of including paricalcitol&#xD;
      and nivolumab as part of the gemcitabine and abraxane chemotherapeutic regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2020</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numer of Adverse Events</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Before Surgery Wks 1 &amp;3, After Surgery Wks 1 &amp;3</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-Paclitaxel</intervention_name>
    <description>Wks 1,2,3 before surgery and Wks 1, 2,3 after surgery</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Wks 1,2,3 before surgery and Wks 1,2,3 after surgery</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <description>Wks 1,2,3, 4 before surgery and Wks 1,2,3 after surgery</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously untreated, apparently resectable adenocarcinoma of the pancreas at&#xD;
             registration.&#xD;
&#xD;
          -  Age greater than or equal to 18 years&#xD;
&#xD;
          -  ECOG performance status of 0-2.&#xD;
&#xD;
          -  Standard laboratory criteria for hematologic, biochemical, and urinary indices within&#xD;
             a range that, in the opinion of the physician, clinically supports enrollment of the&#xD;
             subject on the trial.&#xD;
&#xD;
             a. Note: subjects must have: Creatinine &lt; 2xULN, Neutrophils &gt;1.5x109/L, total&#xD;
             bilirubin &lt; 3xULN, AST &lt;5xULN, ALT &lt;5xULN, and Platelets &gt;100,000/mm3&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with hypercalcemia (blood levels greater than 11.5 mg/dL). In subjects&#xD;
             creatinine clearance &lt;60mL/min, blood calcium levels must be 9.5 mg/dL or lower.&#xD;
&#xD;
          -  Subjects who are currently pregnant, planning to become pregnant, or breast-feeding&#xD;
&#xD;
               1. Females participants of child-bearing potential are required to use an effective&#xD;
                  contraception method (see Appendix A) or abstain from intercourse during&#xD;
                  treatment and for at least 5 months following the last dose&#xD;
&#xD;
               2. Males participants with partners of child-bearing potential are required to use&#xD;
                  an effective contraception method (see Appendix A) or abstain from intercourse&#xD;
                  during treatment and for at least 5 months following the last dose 3. Subjects&#xD;
                  who, in the opinion of the physician, would not be clinically appropriate for&#xD;
                  receipt of the therapy regimen associated with participation 4. Subjects with&#xD;
                  contraindications to immune checkpoint therapy, as follows:&#xD;
&#xD;
               1. Interstitial lung disease that is symptomatic or may interfere with the detection&#xD;
                  and management of suspected drug-related pulmonary toxicity&#xD;
&#xD;
               2. Prior organ allograft or allogeneic bone marrow transplantation&#xD;
&#xD;
               3. Pre-existing thyroid abnormality with thyroid function that cannot be maintained&#xD;
                  in the normal range with medication&#xD;
&#xD;
               4. Active autoimmune disease, except for vitiligo, type 1 diabetes mellitus, asthma,&#xD;
                  atopic dermatitis, or endocrinopathies manageable by hormone replacement; other&#xD;
                  autoimmune conditions may be allowable at the discretion of the principal&#xD;
                  investigator&#xD;
&#xD;
               5. Condition requiring systemic treatment with either corticosteroids&#xD;
&#xD;
                    -  Systemic steroids at physiologic doses (equivalent to dose of oral&#xD;
                       prednisone 10 mg) are permitted. Steroids as anti-emetics for chemotherapy&#xD;
                       are strongly discouraged (see section 5.1.3)&#xD;
&#xD;
                    -  Intranasal, inhaled, topical, intra-articular, and ocular corticosteroids&#xD;
                       with minimal systemic absorption are permitted&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter O'Dwyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter O'Dwyer, MD</last_name>
    <phone>855-216-0098</phone>
    <email>PennCancerTrials@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter O'Dwyer, MD</last_name>
      <phone>855-216-0098</phone>
      <email>PennCancerTrials@emergingmed.com</email>
    </contact>
    <investigator>
      <last_name>Peter O'Dwyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

